John Quisel, Disc Medicine CEO
October 19, 2026 07:00 AM EDT
After FDA rejection, Disc Medicine's 'sun allergy' drug hits home run in Phase 3
Disc Medicine’s treatment for a rare disease that makes sun exposure painful succeeded on all endpoints in a Phase 3 study. The result sets the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source